[The Prognostic Factors for AML Children with CBFβ/MYH11 Positive]

Area of Science:

• Pediatric Oncology
• Hematologic Malignancies
• Molecular Diagnostics

Background:

• Acute myeloid leukemia (AML) in children with the CBFβ/MYH11 fusion gene presents unique prognostic considerations.
• Identifying key factors influencing treatment outcomes is crucial for improving survival rates in this pediatric subpopulation.

Purpose of the Study:

• To investigate the prognostic significance of clinical and genetic factors in pediatric AML patients with CBFβ/MYH11 rearrangement.
• To determine the impact of white blood cell (WBC) count and XRCC-Thr241Met genotype on overall survival (OS) and event-free survival (EFS).

Main Methods:

• Retrospective analysis of clinical data from 28 pediatric AML patients with CBFβ/MYH11 rearrangement.
• Evaluation of overall survival (OS) and event-free survival (EFS) rates.
• Statistical analysis including univariate and Cox multivariate survival analyses.

Main Results:

• Five-year OS and EFS rates were 76.8% and 64.0%, respectively.
• Lower initial WBC counts (<60.0×10^9/L) were associated with significantly higher OS and EFS rates.
• Wild-type XRCC-Thr241Met genotype showed significantly better EFS compared to variant genotypes.

Conclusions:

• Initial WBC level is a significant risk factor for OS in pediatric AML with CBFβ/MYH11.
• Both initial WBC level and XRCC-Thr241Met genotype are critical prognostic factors for EFS in this patient group.